Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes

Journal of Neurology

Volumn 263, Issue 1, 2016, Pages 140-149

  Juryńczyk, Maciej ^a,v   Weinshenker, Brian ^b   Akman Demir, Gulsen ^c   Asgari, Nasrin ^d   Barnes, David ^e   Boggild, Mike ^f   Chaudhuri, Abhijit ^g   D’hooghe, Marie ^h   Evangelou, Nikos ⁱ   Geraldes, Ruth ^j   Illes, Zsolt ^k   Jacob, Anu ^l   Kim, Ho Jin ^m   Kleiter, Ingo ⁿ   Levy, Michael ^o   Marignier, Romain ^p   McGuigan, Christopher ^q   Murray, Katy ^r   Nakashima, Ichiro ^s   Pandit, Lekha ^t   Paul, Friedemann ^u   Pittock, Sean ^b   Selmaj, Krzysztof ^v   de Sèze, Jérôme ^w   Siva, Aksel ^x   Tanasescu, Radu ^i,y   Vukusic, Sandra ^p   Wingerchuk, Dean ^b   Wren, Damian ^e   Leite, Isabel ^a   Palace, Jacqueline ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MAYO CLINIC   (United States)

^c ISTANBUL BILIM UNIVERSITY   (Turkey)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e ST GEORGE S HOSPITAL   (United Kingdom)

^f TOWNSVILLE HOSPITAL   (Australia)

^g QUEEN S HOSPITAL   (United Kingdom)

^h UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

ⁱ UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^j UNIVERSITY OF LISBON   (Portugal)

^k ODENSE UNIVERSITY HOSPITAL   (Denmark)

^l WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^m National Cancer Center   (South Korea)

ⁿ ST JOSEF HOSPITAL   (Germany)

^o JOHNS HOPKINS UNIVERSITY   (United States)

^p HÔPITAL NEUROLOGIQUE   (France)

^q ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^r UNIVERSITY OF EDINBURGH   (United Kingdom)

^s TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^t NITTE UNIVERSITY   (India)

^u CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^v MEDICAL UNIVERSITY OF LODZ   (Poland)

^w UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^x ISTANBUL UNIVERSITY   (Turkey)

^y CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

more..

Author keywords

All demyelinating disease (CNS); Devic s syndrome; Multiple sclerosis; Optic neuritis; Transverse myelitis

Indexed keywords

AQUAPORIN 4; BETA INTERFERON; BIOLOGICAL MARKER; FINGOLIMOD; GLATIRAMER; IMMUNOGLOBULIN G; NATALIZUMAB; RITUXIMAB; AQP4 PROTEIN, HUMAN; AUTOANTIBODY;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DIAGNOSTIC IMAGING; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT ISOLATED OPTIC NEURITIS; BLOOD; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; IMMUNOLOGY; NEUROMYELITIS OPTICA; PATHOLOGY; SYNDROME;

AQUAPORIN 4; AUTOANTIBODIES; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; HUMANS; IMMUNOGLOBULIN G; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; SYNDROME;

EID: 84955687637     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7952-8     Document Type: Article

References (36)

1. Wingerchuk DM, Lennon V, Lucchinetti CF et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815. doi:10.1016/S1474-4422(07)70216-8
2. Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: Lancet 364:2106–2112
3. Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477. doi:10.1084/jem.20050304
4. Palace J, Leite MI, Leite I, Jacob A (2012) A practical guide to the treatment of neuromyelitis optica. Pract Neurol 12:209–214. doi:10.1136/practneurol-2012-000237
5. Juryńczyk M, Craner M, Palace J (2015) Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry 86:20–25. doi:10.1136/jnnp-2014-308984
6. Matthews L, Marasco R, Jenkinson M et al (2013) Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80:1330–1337. doi:10.1212/01.wnl.0000436079.95856.1f
7. Palace J, Leite MI, Nairne A, Vincent A (2010) Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 67:1016–1017. doi:10.1001/archneurol.2010.188
8. Kleiter I, Hellwig K, Berthele A et al (2012) Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica. Arch Neurol 69:239–245. doi:10.1001/archneurol.2011.216
9. Jacob A, Kelly S, Ali R, Optica N (2012) Does Natalizumab Therapy Worsen Neuromyelitis Optica? Neurology 79:1065–1069
10. Juryńczyk M, Zaleski K, Selmaj K (2013) Natalizumab and the development of extensive brain lesions in neuromyelitis optica. J Neurol 260:1919–1921. doi:10.1007/s00415-013-6965-4
11. Min J-H, Kim BJ, Lee KH (2012) Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler J 18:113–115. doi:10.1177/1352458511431973
12. Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79:1273–1277. doi:10.1212/WNL.0b013e31826aac4e
13. Kitley J, Waters P, Woodhall M et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. doi:10.1001/jamaneurol.2013.5857
14. Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474–481. doi:10.1212/WNL.0000000000000101
15. Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76:378–382
16. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174
17. Koch-Henriksen N, Sørensen PS (2010) The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 9:520–532. doi:10.1016/S1474-4422(10)70064-8
18. Tackley G, Kuker W, Palace J (2014) Magnetic resonance imaging in neuromyelitis optica. Mult Scler. doi:10.1177/1352458514531087
19. Kim HJ, Paul F, Lana-Peixoto MA et al (2015) MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 84:1165–1173. doi:10.1212/WNL.0000000000001367
20. Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489. doi:10.1212/01.wnl.0000216139.44259.74
21. Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189. doi:10.1212/WNL.0000000000001729
22. Kitley JL, Leite MI, George JS, Palace J (2012) The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler 18:271–285. doi:10.1177/1352458511406165
23. Kitley J, Leite MI, Küker W et al (2013) Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 70:1375–1381. doi:10.1001/jamaneurol.2013.3890
24. Flanagan EP, Weinshenker BG, Krecke KN et al (2015) Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 72:81–87. doi:10.1001/jamaneurol.2014.2137
25. Kidd D, Burton B, Plant GT, Graham EM (2003) Chronic relapsing inflammatory optic neuropathy (CRION). Brain 126:276–284
26. Petzold A, Plant GT (2014) Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 261:17–26. doi:10.1007/s00415-013-6957-4
27. Paty DW, Oger JJ, Kastrukoff LF et al (1988) MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38:180–185
28. Papeix C, Vidal J-S, de Seze J et al (2007) Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13:256–259. doi:10.1177/1352458506070732
29. Matsuoka T, Matsushita T, Kawano Y et al (2007) Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130:1206–1223. doi:10.1093/brain/awm027
30. Kira J, Itoyama Y, Kikuchi S et al (2014) Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol 14:21. doi:10.1186/1471-2377-14-21
31. Palace J, Rothwell P (1997) New treatments and azathioprine in multiple sclerosis. Lancet 350:261. doi:10.1016/S0140-6736(97)24030-4
32. Michel L, Vukusic S, De Seze J et al (2014) Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J Neurol Neurosurg Psychiatry 85:279–283. doi:10.1136/jnnp-2013-305298
33. Goodkin DE, Rudick RA, VanderBrug Medendorp S et al (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 37:30–40. doi:10.1002/ana.410370108
34. Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688. doi:10.1056/NEJMoa0706383
35. Peabody JW, Luck J, Glassman P et al (2004) Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann Intern Med 141:771–780
36. Waters P, Woodhall M, O’Connor KC et al (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflam 2:e89